Anadys Pharmaceuticals (ANDS) Inactive 10-K2009 FY Annual report

Filed: 1 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: albinterferon, anomalously, arm, ASC, ascompleteEarlyVirologicalResponse, asRapidVirologicalResponse, auditor, Australia, barrier, Black, Brazil, burn, Canada, career, cEVR, characterized, Codification, codified, consummating, Counsel, Cowen, cum, debate, decease, departed, departing, deposit, displace, element, encouraged, encouraging, endpoint, European, foundation, genetic, incidence, instance, interferonalpha, Intron, itching, KPMG, licensee, LLC, lowest, maculopapular, Malta, maximal, Mexico, Morocco, municipal, narlaprevir, nongovernmental, Oberlin, ofSustainedVirologicalResponse, onset, outlicensing, par, partnership, peg, peter, Phenomix, Placement, plateau, presentedin, randomized, rash, rebound, red, regular, remit, respiratory, Roferon, roll, rollforward, RVR, settled, Shippensburg, slover, Sloverjoined, SOC, spent, statutory, steady, streamlined, Suite, surface, Taiwan, undetectable, vitrodata

Removed: acceleration, achievability, acknowledgment, Albuferon, Allergan, ascending, aspect, assign, assured, attempt, Beckman, biomedical, British, Bulletin, CFO, Columbia, considerable, Consulting, Coulter, creditable, determinable, devote, DeVry, Diagnostic, difficulty, diversity, Division, DNA, enrolling, essential, estate, evidenced, expanded, FIN, fit, fixed, flow, fourth, funded, Glanville, Gloverjoined, guidance, identifying, incurrence, Inex, Inflazyme, Institute, integrate, integrating, integration, interpretation, investing, loan, Master, Merryfield, Mesa, milestone, outlined, Pepperdine, persuasive, planning, Plough, pollution, Polytechnic, promoted, real, realize, receipt, recently, refundable, remediation, rendered, resignation, Row, SAB, Schering, SmithKline, stipulated, substantive, tenure, Torrey, Treasurer, uncertainty, unforeseen, unwilling, upfront, vote, worked, written, Yaroshevsky

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANDS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements on Form S-8 (No.’s 333-113954, 333-120647, 333-129716, 333-137114, 333-145889, 333-154743 and 333-162776) and Form S-3 (No.’s 333-124231, 333-132729 and 333-158342) of Anadys Pharmaceuticals, Inc. and in the related Prospectus, of our reports dated March 1, 2010, with respect to the consolidated financial statements of Anadys Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of Anadys Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2009.

/s/ Ernst & Young LLP

San Diego, California
March 1, 2010